Brian Frenzel, President, Chief Executive Officer and Director, Tosk, joining the Summit from Mountain View, CA

Tosk is working to improve the quality of life and outcomes for patients by preventing the adverse side effects of existing cancer therapies, and blocking the activity of cancer genes. Brian will join the November Summit to unveil a brand new lead project that he and his colleagues have developed this year.

Brian is a highly experienced biomedical company executive, previously serving as CEO of Centaur Pharmaceuticals, CEO of Adeza Biomedical, CEO of Vesta Medical, and COO of Genelabs Technologies, all of which went public or were acquired by large pharmaceutical companies. Earlier in his career, He was director of corporate planning at Syntex Corporation, a principal at Booz, Allen & Hamilton, a consultant at the Boston Consulting Group, and a lieutenant in the United States Navy Nuclear Power Program. Brian holds a BS in physics and an MBA from Stanford University. You may have met Brian at previous Cavendish Forums, in his concurrent role with Band of Angels.

Meet Brian and Tosk by logging in to Cavendish IQ.

Robert Boyce, Chief Executive Officer, Plakous Therapeutics, joining in from Winston-Salem, North Carolina

Plakous Therapeutics, established in 2016, has developed a patent-pending, placenta-derived, acellular platform biotherapeutic for the prevention of the rare pediatric disease, Necrotizing Enterocolitis (NEC).

In June 2020, Plakous received both Orphan Drug and Rare Pediatric Disease designations from the FDA, and, in July 2020, Plakous received a $1.72M fast track Phase I and II SBIR grant from the NIH for NEC. This grant includes funding for the pre-clinical and potency experiments required for our IND filing. Most recently, the company signed an agreement with the Mayo Clinic to develop a natural history study for NEC.

Meet Robert and learn more about Plakous by logging in to Cavendish IQ.

Dillon Galynsky, Co-Founder and Chief Executive Officer, HUSH, joining the Summit from New York City

HUSH is on a mission to rid the world of secondhand smoke. The team will introduce a new handheld filtration technology for both cannabis and tobacco, providing users the ability to capture all fumes and odor. As regulations and cultural shifts continue to favor smokeless and odorless consumption, HUSH is positioned to be the leading consumer product to provide a game-changing solution. The company presents dynamic domestic and international intellectual property ownership, and the team includes members of award-winning ELEVEN, and a former RI State Department of Health Executive Director.

Meet Dillon and learn more about HUSH’s work by logging in to Cavendish IQ.